SPL

1.02%

9.7¢ starpharma holdings limited

FDA meeting, page-3

First 3 Last

Share
Profile

Follow
thrasher

4,929 Posts.

285

22/03/19

10:12

Post #: 37849099
Share

Originally posted by stockrock: ↑

Hi

The CRL would be more detailed than the two words "confirmatory data", but it won't be so prescriptive as to eliminate all ambiguity.

As such, when responding to a CRL there is always an eliminate of guesswork - albeit an educated and informed guess. Hiring ex-FDA consultants is a given when responding to a CRL, each and every pharma company would take this step. It is prudent and expected of Starpharma to do so.

As such, having these consultants don't give me any extra confidence that they will get a favourable outcome with the FDA in this meeting.

Heard of the song "Ironic"? This line springs to mind ... "It's like having 10,000 spoons, when all you need is a knife".

Doesn't matter how many dollars you spend on advice, if the regulatory body wants a knife and you give them 10,000 different types of spoons .. you will still get knocked back.

Something to keep in mind is that the FDA chooses its words very clearly. If they needed more clinical data, they ask for clinical data in their CRL.

If they want another trial, they ask for confirmatory data.

Starpharma are giving them more clinical data (another spoon).

So all I am saying is that Starpharma are going to be fighting an uphill battle at this next FDA meeting. I am not saying they can't win, I am just pointing out that it won't be easy and the odds are currently against them.

Having partial approval for one indication is not ideal, but possible and better than no approved product this year.. but that is pure speculation on our part as we don't know what is in the CRL. It may sound logical, but there are so many possibilities out there ... how do I justify to myself as an investor to place my hard earned cash based on two words "confirmatory data". Especially when I know what that means.

It's risk awareness and capital protection that I am advocating, and my risk appetite is different to everybody else. However I feel an obligation as part of an investor forum and former shareholder to share this view.

Expand

Always respected your views just don’t completely agree with it this time confirmatory data can come from existing data even fda guidelines say this, could be Starpharma also present a plan to provide new data after some adjusted approval. Lots of possible outcomes I just don’t think worst outcome will be the result.

SPL Price at posting: $1.00 Sentiment: Hold Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

A3D

Defence MOU for propulsion systems pushes Aurora Lab shares higher

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

CXU

Cauldron Energy reports "excellent" uranium assays in latest drill run

SHN

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

NWH

NRW Holdings inks $109M deal with BHP for works at Jimblebar

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

IMA

Issues emerging as Australian companies tackle critical minerals challenge

RAG

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

TIG

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

There are more pages in this discussion • 12 more messages in this thread...

First 3 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 9.7¢		Change -0.001(1.02%)		Mkt cap ! $40.48M

Open	High	Low	Value	Volume
9.6¢	10.0¢	9.6¢	$5.703K	58.16K

Buyers (Bids)

No.	Vol.	Price($)
1	100000	9.6¢

Sellers (Offers)

Price($)	Vol.	No.
9.8¢	20000	1

View Market Depth

No.	Vol.	Price($)
2	8325	0.095
3	160000	0.094
2	9659	0.093
2	134306	0.092
1	11000	0.091

Price($)	Vol.	No.
0.098	20000	1
0.100	4000	1
0.105	143620	3
0.110	198286	10
0.115	103400	3

Last trade - 15.41pm 11/10/2024 (20 minute delay)

SPL (ASX) Chart

FDA meeting, page-3

Defence MOU for propulsion systems pushes Aurora Lab shares higher

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Cauldron Energy reports "excellent" uranium assays in latest drill run

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

NRW Holdings inks $109M deal with BHP for works at Jimblebar

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

Issues emerging as Australian companies tackle critical minerals challenge

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

FDA meeting, page-3

Top Stories

Defence MOU for propulsion systems pushes Aurora Lab shares higher

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Cauldron Energy reports "excellent" uranium assays in latest drill run

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

NRW Holdings inks $109M deal with BHP for works at Jimblebar

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

Issues emerging as Australian companies tackle critical minerals challenge

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News